Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PENICILLIN V (POTASSIUM)

All products: not a benefit

Other products in the same Health Canada class (J01C) — coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

Nadopen-V · DIN 00018635 · 25mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.Discontinued 2006-08-25 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nadopen-V · DIN 00018635 Manufacturer: Nadeau Laboratory Ltd.; listing date 1996-10-01 Daily cost (source): $1.0700 Health Canada: Cancelled post market since 2006-08-25 · brand NADOPEN V 200 · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Powder for solution · route Oral · ingredients PENICILLIN V POTASSIUM 40000 UNIT/ML · company Lioh inc. · schedule Prescription
Check this DIN again · Health Canada product record

Nadopen-V: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1512 · Verify on the e-Formulary ↗ (DIN 00018635)

Source record
DIN 00018635: Nadopen-V Raw flags: notABenefit=Y, sec3=Y Item: 081216035; group id 29; item number 0060; lccId None; manufacturer id NDA Source form: O/L; strength: 25mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00018635 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1512
Interchangeable products
Apo-Pen V-K · DIN 00642223 · $0.0535
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFUROXIME AXETIL · General benefit (7), Listed, not a benefit (2) Indications CEFTIN (cefuroxime axetil for oral suspension) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: • Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes. PM: https://pdf.hres.ca/dpd_pm/00081954.PDF; date 2025-10-03; DIN 02212307; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PEN-VK (Penicillin V Potassium (Phenoxymethylpenicillin Potassium)) is indicated for: • Mild to moderately severe infections caused by penicillin V sensitive microorganisms including streptococcal pharyngitis, staphylococcal infection without bacteremia and pneumococcal infections. Therapy should be guided by bacteriologic sensitivity tests and clinical response. Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with potassium phenoxymethyl penicillin during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of potassium phenoxymethyl penicillin: • Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Note: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. • Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. • Staphylococcal infections sensitive to penicillin V: Mild infections of the… https://pdf.hres.ca/dpd_pm/00081311.PDF PM date: August 1, 2025 Source product: PEN-VK; DIN 00642215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Nadopen-V: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026